CORE--CLINICAL/BASIC SCIENCE INTERFACE CORE

临床研究实验室是核心资源实验室， 加州大学洛杉矶分校的艾滋病研究团体。 此外，由于其独特的 资源，也允许校外合作。 实验室 成立于1991年，最初专注于支持临床试验 和应用临床标本来回答基础科学问题。 1993年，该实验室的工作重点重新调整， 需要获取特定类型临床标本的研究 为了回答关于免疫破坏的发病机制的问题， 在艾滋病和艾滋病相关的恶性肿瘤的发展。 该实验室拥有超过15，000份血清的计算机化库存 样本、600份血浆样本、800份冷冻活淋巴细胞制剂， 以及提供卡波西肉瘤细胞的连续新鲜分离 和艾滋病淋巴瘤细胞用于基础科学研究。 将样品 与临床状态和结果相关。 大多数患者都出现了 一种快速、简便的血清学检测方法，用于检测 新生儿，排除Rochelimea作为KS的病原体，检查了 细胞因子紊乱与肿瘤发生的关系 淋巴瘤，确定了受体后途径的关键分子， KS中导致增殖的信号翻译，证明了 淋巴瘤中重链的利用是非随机的， 艾滋病恶性肿瘤的克隆性，和分离的基因片段， 与经典和艾滋病相关KS有关的生物体。 校内和校外的研究人员可以自由提出体外 利用实验室的资源。 然而，优先事项是 给予种子赠款意识，校内研究，这些研究 这与我们理解 HIV感染免疫发病机制。 所有研究均由 并与行政部门进行了讨论 以马克思 对常规样品处理、储存、 以及RNA和DNA的分离。 淋巴瘤和卡波西肉瘤细胞系是 免费提供。 迄今为止，核心小组已为20多名调查员提供了广泛的服务， 需要临床材料的基础科学问题。 独特的能力 不仅提供稀有标本和细胞系， 将结果置于背景中的临床信息是最大的 这个核心的力量。 预计其中一些 有关的研究工作将于一九九四至九五年度展开新药剂的临床试验。

The clinical investigations laboratory is a core resource laboratory for the UCLA HIV research community. In addition, because of its unique resources, extramural collaborations are also allowed. The laboratory was started in 1991 and initially focused on supporting clinical trials and application of clinical specimens to answer basic science questions. In 1993, the laboratory was refocused to support basic science investigations that needed access to specific types of clinical specimens in order to answer questions on the pathogenesis of immune destruction in HIV disease and the development of AIDS related malignancies. The laboratory houses a computerized inventory of over 15,000 serum samples, 600 plasma samples, 800 frozen viable lymphocyte preparations, as well as provides continuous fresh isolation of Kaposi sarcoma cells and AIDS lymphoma cells for basic science studies. The samples are linked to clinical status and outcome. Most patients have develop a rapid, simple serologic assay for the detection of HIV infection in the newborn, excluded Rochelimea as a causative agent for KS, examined the relationship between cytokine perturbations and the development of lymphomas, identified key molecules in the post-receptor pathway of signal translation in KS leading to proliferation, demonstrated that heavy chain utilization in lymphomas is non-random, investigated the clonality of AIDS malignancies, and isolated genetic fragments of a organism that is linked to classical and AIDS-related KS. Intramural and extramural investigators are free to propose in vitro studies using the resources of the laboratory. However, priority is given to seed grant awareness, intramural studies, and those studies which are consistent with our overall goal of understanding the immunopathogenesis of HIV infection. All studies are reviewed by the director for their scientific merit and discussed with the executive committee. Charges are levied for routine sample processing, storage, and isolation of RNA and DNA. Lymphoma and Kaposi sarcoma cell lines are provided at no charge. To date, the core has serviced over 20 investigators on a wide range of basic science questions requiring clinical materials. The unique ability to provide not only rare specimens and cell lines but the associated clinical information that places the results in context are the greatest strength of this core. It is anticipated that several of these investigations will lead to clinical trials of novel agents in 1994-95.